search

Paris (France), February 6, 2023 – 7:30 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), […]

OX425 is a novel DDR Decoy Agonist which also mediates multiple immunostimulatory effects, making it a promising candidate for combination […]

Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally Cash position of €26.9 million as of June […]

Paris (France), September 1st, 2022 – 8 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North[1]: ONXEO), a […]

Company to submit delisting request to Nasdaq   Paris (France), August 17, 2022 – 08:00 pm CEST – Onxeo S.A. […]

Paris (France), July 29, 2022 – 06:30 pm CEST – Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North: ONXEO), a […]

Paris (France), July 12, 2022 – 07:00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

Onxeo to initiate its first phase 1b/2 trial in the United States in patients with solid tumors   Paris (France), […]

All resolutions voted in accordance with Board of Directors’ recommendations Khalil Barrage, Managing Director of Invus’ public equity investments division, […]

Agarwal is Currently Chairwoman of Onxeo’s Board, a Position Held Since June 2021 Company Outlines Development Strategy Plans Including Preparation […]

Cash position of €17.9 million as of December 31, 2021 Additional financing of €12 million subscribed by historical shareholders Invus […]

AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models AsiDNA™ proven to protect healthy cells when […]

Paris (France), January 3rd, 2022 – 6:00 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), […]

Paris (France), January 13, 2022 – 6 pm CET – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), […]

These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022   Paris (France), March 9, 2022 – 7:00 […]

Bryan Giraudo, COO & CFO of U.S. biopharmaceutical company Gossamer Bio, joins the Company’s Board as independent member   Paris […]

Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy […]

Cash position of €24.5 million as of June 30, 2021, providing financial visibility until the end of 2022 and enabling […]

All resolutions voted in accordance with Board of Directors’ recommendations Shefali Agarwal, MD, a clinical development expert in oncology, is […]

This new patent protects both AsiDNA™ in combination with a PARP inhibitor and the use of the combination for the […]

This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of […]

Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]

This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]

Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]

This study is supported by a grant from the European Fight Kids Cancer program[1]   Paris (France), February 4, 2021 […]

Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]

This financing extends the Company’s cash horizon to the 3rd quarter of 2022   Paris (France), January 28, 2021 – […]

Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]